Arrowhead Pharmaceuticals Presents Preclinical Data on RNAi-Based Obesity Program

Key points:

  • Arrowhead’s ARO-INHBE shows promise in preclinical studies, reducing body weight by 19% while preserving lean mass.
  • The RNAi-based therapy targets the INHBE gene, potentially offering a novel approach to treating obesity and metabolic diseases.
  • Arrowhead plans to file for regulatory clearance to begin clinical studies of ARO-INHBE in late 2024.


Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has unveiled promising preclinical data for its innovative obesity treatment, ARO-INHBE, at the American Diabetes Association’s 84th Scientific Sessions. This RNA interference (RNAi) based therapy targets the INHBE gene, offering a potential new avenue in the fight against obesity and metabolic diseases.

                                                                      Image Source: Arrowhead Pharmaceuticals

In an era where obesity treatments are advancing rapidly, ARO-INHBE stands out for its ability to reduce body weight without sacrificing lean mass – a common drawback of existing therapies. Preclinical studies in obese and diabetic mouse models demonstrated a 19% suppression in body weight and a 26% loss in fat mass, while crucially preserving lean mass.

Dr. James Hamilton, Chief of Discovery and Translational Medicine at Arrowhead, emphasized the significance of these findings: “Our preclinical data suggest that INHBE reduction with siRNA is a promising new approach to address obesity and metabolic diseases. The preservation of lean mass, in particular, addresses a key limitation of current obesity treatments.”

The global obesity treatment market is projected to reach $100 billion by 2030, according to J.P. Morgan analysts. ARO-INHBE’s unique mechanism of action could potentially capture a significant share of this rapidly growing market.

Arrowhead plans to file for regulatory clearance to begin clinical studies of ARO-INHBE in late 2024, marking a significant step towards bringing this innovative therapy to patients. The company will discuss ARO-INHBE and other preclinical programs addressing obesity and metabolic diseases in its upcoming R&D Webinar on August 15, 2024.

As obesity continues to be a global health crisis, ARO-INHBE represents a promising new tool in the medical community’s arsenal. Its potential to reduce weight without compromising muscle mass could revolutionize obesity treatment, offering hope to millions struggling with weight-related health issues. 

Weight loss


Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BioMediaHub Logo